Biogen, Dravet and Stoke

Biogen, Stoke Therapeutics Ink Deal to Develop Zorevunersen for Dravet Syndrome
Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights to commercialize the treatment outside of North America.
Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m.
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome is a genetic developmental and epileptic encephalopathy characterised by cognitive and behavioural impairments and recurrent seizures.
3STOK, BIIB : Biogen Strengthens Pipeline With Stoke Therapeutic ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
FierceBiotech4d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
News Medical on MSN4d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
National Institute for Health and Care Excellence2d
New life-changing treatment option recommended to help control seizures for type of rare epilepsy
New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...
BioPharma Dive3d
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...